JP2017523203A - 海産物ペプチドおよび魚類ヌクレオチド、その組成物および血糖を低下させるためのその使用 - Google Patents
海産物ペプチドおよび魚類ヌクレオチド、その組成物および血糖を低下させるためのその使用 Download PDFInfo
- Publication number
- JP2017523203A JP2017523203A JP2017505501A JP2017505501A JP2017523203A JP 2017523203 A JP2017523203 A JP 2017523203A JP 2017505501 A JP2017505501 A JP 2017505501A JP 2017505501 A JP2017505501 A JP 2017505501A JP 2017523203 A JP2017523203 A JP 2017523203A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- marine
- peptide
- combination
- marine peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 158
- 239000002773 nucleotide Substances 0.000 title claims abstract description 87
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 86
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 61
- 239000008280 blood Substances 0.000 title claims abstract description 48
- 210000004369 blood Anatomy 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 title description 28
- 238000000034 method Methods 0.000 claims abstract description 55
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 26
- 239000008103 glucose Substances 0.000 claims abstract description 26
- 101800001586 Ghrelin Proteins 0.000 claims abstract description 23
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims abstract description 23
- 230000000291 postprandial effect Effects 0.000 claims abstract description 22
- 235000012054 meals Nutrition 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims description 78
- 102400000442 Ghrelin-28 Human genes 0.000 claims description 22
- 230000037396 body weight Effects 0.000 claims description 22
- 235000015872 dietary supplement Nutrition 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 12
- 230000002641 glycemic effect Effects 0.000 claims description 9
- 235000019627 satiety Nutrition 0.000 claims description 7
- 230000036186 satiety Effects 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000001280 Prediabetic State Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 3
- 102000012004 Ghrelin Human genes 0.000 abstract 1
- 239000012503 blood component Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 description 20
- 108010046377 Whey Proteins Proteins 0.000 description 16
- 102000007544 Whey Proteins Human genes 0.000 description 16
- 235000013376 functional food Nutrition 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 230000037406 food intake Effects 0.000 description 11
- 239000005862 Whey Substances 0.000 description 10
- 239000005018 casein Substances 0.000 description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 235000021240 caseins Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000003531 protein hydrolysate Substances 0.000 description 9
- 235000014102 seafood Nutrition 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 235000021119 whey protein Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000021152 breakfast Nutrition 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000003642 hunger Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 3
- 241000276438 Gadus morhua Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000019525 fullness Nutrition 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 108010028690 Fish Proteins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 235000013332 fish product Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical group [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000006206 intraperitoneal dosage form Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- -1 sodium salts Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/20—Fish extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Pediatric Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Description
本明細書では、魚類産物および魚類副産物ならびに健康、食品、栄養および医学的治療におけるそれらの使用が提供される。
食後血糖(または血糖症)は、関連する高インスリン血症および脂肪血症とともに、例えば肥満症、2型糖尿病および心血管疾患といった慢性代謝性疾患の発症に関与している。食後血糖症または食後の血糖変動が、こうした状態の発現または認知および運動のパフォーマンスの障害と関連していることが証明されている。
本明細書では、被験体の血液中の食後のグルコース濃度を低下させる方法であって、前記被験体の血液中のグルコース濃度を低下させるのに十分な海産物ペプチドと魚類ヌクレオチドとの組み合わせ物の有効量を、食前または食中に前記被験体に投与することを含む前記方法が提供される。
本明細書中の記述および添付の特許請求の範囲に関して、文脈上明示がない限り、単数形「a」、「an」および「the」には複数の指示対象が含まれる。したがって、例えば「a compound」への言及は複数の化合物を指す。さらに、特に明記しない限り、「または」の使用は「および/または」を意味する。同様に、「comprise,」、「comprises,」、「comprising」、「include,」、「includes,」および「including」は互換的であり、限定を意図するものではない。
a)海産物原材料と水と酵素とを混合して、海産物材料混合物を形成させること;特に、酵素はエンドペプチダーゼから選択される;
b)前記海産物材料混合物を均質化してホモジネートを形成させること;
c)約45分間までの期間にわたって前記ホモジネートを加熱して、インキュベート物(incubate)を形成させること;
d)前記酵素を不活性化させて、不活性化された酵素を有するインキュベート物を形成させること;
e)任意に、前記インキュベート物から骨を分離して、水溶性タンパク質に富む画分を有するインキュベート物を形成させること;
f)前記インキュベート物からペプチドに富む水溶性画分を分離して、ペプチド加水分解物を得ること;
g)任意に、前記加水分解物をろ過または限外ろ過して微小粒子を除去すること;および
h)任意に、前記加水分解物を噴霧乾燥して自由流動性粉末を形成させること;
を含む海産物ペプチドの製造方法が提供される。
ペプチド(分子量(Da)) 量(乾燥重量基準)
>20KDa 0〜5%
15KDa〜20KDa 0〜5%
10KDa〜15KDa 0〜5%
8KDa〜10KDa 0〜5%
6KDa〜8KDa 0〜5%
4KDa〜6KDa 0〜10%
2KDa〜4KDa 0〜15%
1KDa〜2KDa 0〜50%
0.5KDa〜1KDa 0〜50%
0.2KDa〜0.5KDa 0〜75%
<0.2KDa 0〜75%。
ペプチド(分子量) 量(乾燥重量基準)
>20KDa 約<0.1%
15KDa〜20KDa 約<0.1
10KDa〜15KDa 約<0.1
8KDa〜10KDa 約0.1
6KDa〜8KDa 約0.5%
4KDa〜6KDa 約1.9
2KDa〜4KDa 約6.3
1KDa〜2KDa 約13.0
0.5KDa〜1KDa 約18.5
0.2KDa〜0.5KDa 約23.8
<0.2KDa 約24.0
遊離AA 0〜20%、特に約3.5
EAA/NEAA比率 0.4〜0.9、特に約0.7。
アミノ酸の平均Mw=132
ペプチドにおいて存在する場合のアミノ酸の平均Mw=113.5
存在する最小の可能なジペプチド=グリシル−グリシン=Mw132
存在する最大の可能なジペプチド=トリプチル−トリプトファン=Mw390。
実施例1
下記の4つの異なる食物を用いて、12名の健康な男性被験者を含めて二重盲検試験を行った。
(1)大西洋タラからの魚切り身で作製された魚類タンパク加水分解物、
(2)乳清タンパク加水分解物、または
(3)魚類タンパク加水分解物+大西洋タラ(ガドゥス・モルア(Gadus morhua))の白子から抽出されたDNAナトリウムの形態の海産物ヌクレオチド
のいずれかを補給したものを水に溶解させて、摂取前にクリーム状の飲料を形成させた。混合比:粉末1g+冷水4ml。
・体重1kg当たり20mgのペプチドに相当する量
で与え、したがって所与の量を被験者の体重に合わせた。
被験者は絶食し、この来院の前に朝食をとることは許可されず、午前中に来院した。バイタルサインおよび摂取前の血液サンプルを採取した。食物の摂取後に、以下の時点で血液サンプルを採取した:20分、40分、60分、80分、100分および120分。
被験者は絶食し、この来院の前に朝食をとらないよう指示されていた。摂取前の血液サンプルを採取した。食物の摂取後に、以下の時点で血液を採取した:20分、40分、60分、80分、100分および120分。
被験者は絶食し、この来院の前に朝食をとらないよう指示されていた。摂取前の血液サンプルを採取した。食物の摂取が完了した後に、以下の時点で血液を採取する:20分、40分、60分、80分、100分および120分。
被験者は絶食し、この来院の前に朝食をとらないよう指示されていた。摂取前の血液サンプルを採取した。食物の摂取後に、以下の時点で血液を採取した:20分、40分、60分、80分、100分および120分。
12名の参加者全員の平均応答を取得し、かつ、ベースライン(図中のy軸上の0)を上回る血液1L当たりのグルコースmmol数に関する陽性応答の和を、負の値(すなわちベースラインを下回る値。これはインスリンのリバウンド効果を表す)を含めずに用いることによって曲線下面積を算出し、以下の結果を得た:
1.対照食物:5.2mmol/L
2.乳清ペプチド食物:5.2mmol/L
3.海産物ペプチド食物:4.6mmol/L
4.海産物ペプチド+海産物ヌクレオチド食物:4.2mmol/L。
1.対照食物と乳清ペプチド食物との比較:相違なし
2.対照食物と海産物ペプチド食物との比較:海産物ペプチドにより、食後血糖応答が13%低下
3.乳清ペプチド食物と海産物ペプチド食物との比較:海産物ペプチドにより、食後血糖応答が13%低下
4.対照食物と海産物ペプチド+海産物ヌクレオチド食物との比較:海産物ペプチド+海産物ヌクレオチドにより、食後血糖応答が19%低下。
海産物ペプチドによって、対照食物および乳清ペプチド食物と比較して、食後血糖ピークがそれぞれ0.7mmol/Lおよび0.8mmol/L低下した。これらは、それぞれ33%および35%に相当する。
食物の摂取後の4つの異なる時間に、グレリン濃度を測定した。食後60分でのグレリンの負のピークを仮定して、分析により以下のことが判明した:
1.対照食物:−14.3ng/L
2.乳清ペプチド(WPH)食物:−21.2ng/L
3.海産物ペプチド食物:−26.6ng/L
4.海産物ペプチド+海産物ヌクレオチド食物:−3.5ng/L。
1.対照食物:0.76ng/i
2.乳清ペプチド(WPH)食物:0.28ng/L
3.海産物ペプチド食物:0.99ng/L
4.海産物ペプチド+海産物ヌクレオチド食物:0.61ng/L。
Claims (25)
- 被験体の血液中の食後のグルコース濃度を低下させる方法であって、前記被験体の血液中のグルコース濃度を低下させるのに十分なペプチド海産物ペプチドと魚類ヌクレオチドとの組み合わせ物の有効量を前記被験体に投与することを含み、ここで、前記組み合わせ物を、食前または食中に前記被験体に投与する、前記方法。
- 前記被験体がヒトである、請求項1に記載の方法。
- 前記被験体がそのような低下を必要としている、請求項1または2に記載の方法。
- 前記海産物ペプチドを、前記被験体の体重1kg当たり約5mg〜約50mgの量で提供する、請求項1から3までのいずれか1項に記載の方法。
- 前記海産物ペプチドを、前記被験体の体重1kg当たり約20mgの量で提供する、請求項4に記載の方法。
- 前記被験体のインスリン抵抗性を低下させるのに十分な期間にわたって、前記被験体に前記組み合わせ物を投与する、請求項1から5までのいずれか1項に記載の方法。
- 6以上のHbA1Cレベルを有する被験体に、前記HbA1Cレベルを低下させるための期間にわたって前記組み合わせ物を投与する、請求項1から5までのいずれか1項に記載の方法。
- 前記HbA1Cレベルが6.5超である、請求項7に記載の方法。
- 前記HbA1Cレベルが7超である、請求項8に記載の方法。
- 被験体の血液中の食後のGLP−1濃度レベルを高める方法であって、そのGLPレベルの上昇を必要とする前記被験体に、前記被験体の体重1kg当たり約20mgの海産物ペプチドの有効量を投与することを含み、ここで、前記海産物ペプチドを食前または食中に前記被験体に投与し、かつ前記海産物ペプチドを海産物ヌクレオチドの実質的な非存在下に投与する、前記方法。
- 被験体の血液中の食後のグレリン濃度レベルを低下させる方法であって、そのグレリンレベルの低下を必要とする前記被験体に海産物ペプチドの有効量を投与することを含み、ここで、前記海産物ペプチドを海産物ヌクレオチドの実質的な非存在下に提供する、前記方法。
- 被験体に満腹感を与える方法であって、それを必要とする前記被験体に被験体の体重1kg当たり約20mg〜約25mgの海産物ペプチドを投与することを含み、ここで、前記海産物ペプチドを海産物ヌクレオチドの実質的な非存在下に提供する、前記方法。
- 前記被験体がヒトである、請求項10から12までのいずれか1項に記載の方法。
- 前記組み合わせ物を、前記被験体におけるグルコースレベルを管理するための食品として提供する、請求項1から9までのいずれか1項に記載の方法。
- 前記組み合わせ物を、糖尿病前症または糖尿病からなる群から選択される状態を治療するための医薬調剤として提供する、請求項1から9までのいずれか1項に記載の方法。
- 前記組み合わせ物を、血糖の健康を維持するための栄養補助食品において提供する、請求項1から9までのいずれか1項に記載の方法。
- 前記海産物ペプチドを、前記被験体におけるGLP−1の健康を管理するための栄養補助食品として提供する、請求項10に記載の方法。
- 前記海産物ペプチドを、前記被験体におけるGLP−1レベルを管理するための食品として提供する、請求項10に記載の方法。
- 前記海産物ペプチドを、被験体におけるグレリンの健康を管理するための栄養補助食品として提供する、請求項11に記載の方法。
- 前記海産物ペプチドを、被験体におけるグレリンレベルを管理するための食品として提供する、請求項11に記載の方法。
- 前記海産物ペプチドを、肥満症を治療するための医薬調剤として提供する、請求項10から13までのいずれか1項に記載の方法。
- 前記組み合わせ物を、健康な身体を維持するための栄養補助食品において提供する、請求項10から13までのいずれか1項に記載の方法。
- 前記魚類ヌクレオチドを、前記海産物ペプチドの重量の約25%の量で提供する、請求項1から21までのいずれか1項に記載の方法。
- 前記ペプチドを、25mg、50mg、75mg、100mg、125mg、150mg、175mg、200mg、225mg、250mg、275mg、300mg、325mg、350mg、400mg、425mg、450mg、475mg、500mg、1000mg、1500mg、2000mg、2500mgおよび3000mgからなる群から選択される量の少なくとも1単位用量として投与する、請求項19から21までのいずれか1項に記載の方法。
- 単離された海産物ペプチドと単離された魚類ヌクレオチドとの組み合わせ物を、前記組み合わせ物の全重量の約10:1の重量比で含有し、ここで、前記組み合わせ物が、被験体における血中グルコースレベルを低下させるのに有効な量で提供される、組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462031855P | 2014-07-31 | 2014-07-31 | |
US62/031,855 | 2014-07-31 | ||
PCT/EP2015/067451 WO2016016350A1 (en) | 2014-07-31 | 2015-07-30 | Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017523203A true JP2017523203A (ja) | 2017-08-17 |
JP6829186B2 JP6829186B2 (ja) | 2021-02-10 |
Family
ID=53773438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017505501A Active JP6829186B2 (ja) | 2014-07-31 | 2015-07-30 | 海産物ペプチドおよび魚類ヌクレオチド、その組成物および血糖を低下させるためのその使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10213473B2 (ja) |
EP (1) | EP3174548B1 (ja) |
JP (1) | JP6829186B2 (ja) |
CN (1) | CN106573034B (ja) |
BR (1) | BR112017001589A2 (ja) |
ES (1) | ES2815351T3 (ja) |
MX (1) | MX2017000878A (ja) |
RU (1) | RU2713935C1 (ja) |
WO (1) | WO2016016350A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021083958A1 (en) * | 2019-10-29 | 2021-05-06 | Specialites Pet Food | Novel peptides inducing satiety |
FR3141617A1 (fr) * | 2022-11-08 | 2024-05-10 | Laboratoire Dielen | Composition pour son utilisation dans le traitement d’un syndrome de l'intestin irritable et/ou dans le traitement d’une hyperperméabilité intestinale. |
WO2024117916A1 (en) * | 2022-12-01 | 2024-06-06 | Calanus As | Bioactive peptide fraction and its use in enhancing muscle growth |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO315184B1 (no) * | 2001-09-26 | 2003-07-28 | Firmenich & Cie | Anvendelse av en sammensetning basert på fiskemelke for fremstilling av etpreparat som öker immunoglobulinproduksjonen |
NO320667B1 (no) * | 2004-02-02 | 2006-01-16 | Einar Lied | Andvendelse av en sammensetning basert på fiskekjøtt for fremstilling av et preparat som reduserer økningen i blodglukose etter fødeinntak |
US7466090B2 (en) | 2004-08-30 | 2008-12-16 | Hunter Douglas Inc. | Apparatus, software and method for controlling the operation of a window covering |
GB0717911D0 (en) * | 2007-09-14 | 2007-10-24 | Univ Stirling | Vaccine |
FR2927335B1 (fr) * | 2008-02-12 | 2012-04-20 | Cie Des Peches Saint Malo Sante | Hydrolysat de proteines de poissons presentant une activite satietogene, compositions nutraceutiques et pharmacologiques comprenant un tel hydrolysat et procede d'obtention |
-
2015
- 2015-07-30 BR BR112017001589-7A patent/BR112017001589A2/pt not_active IP Right Cessation
- 2015-07-30 JP JP2017505501A patent/JP6829186B2/ja active Active
- 2015-07-30 RU RU2017106241A patent/RU2713935C1/ru active
- 2015-07-30 US US15/329,953 patent/US10213473B2/en active Active
- 2015-07-30 WO PCT/EP2015/067451 patent/WO2016016350A1/en active Application Filing
- 2015-07-30 MX MX2017000878A patent/MX2017000878A/es unknown
- 2015-07-30 ES ES15745185T patent/ES2815351T3/es active Active
- 2015-07-30 CN CN201580039721.6A patent/CN106573034B/zh active Active
- 2015-07-30 EP EP15745185.7A patent/EP3174548B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112017001589A2 (pt) | 2018-01-30 |
CN106573034A (zh) | 2017-04-19 |
US10213473B2 (en) | 2019-02-26 |
ES2815351T3 (es) | 2021-03-29 |
RU2713935C1 (ru) | 2020-02-11 |
EP3174548A1 (en) | 2017-06-07 |
MX2017000878A (es) | 2017-05-04 |
EP3174548B1 (en) | 2020-07-22 |
CN106573034B (zh) | 2021-12-17 |
US20170258866A1 (en) | 2017-09-14 |
JP6829186B2 (ja) | 2021-02-10 |
WO2016016350A1 (en) | 2016-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200412990A (en) | Nutritional compositions | |
KR20070112811A (ko) | 포도당내성을 개선시키기 위한 아미노산 조성물 | |
US20050009734A1 (en) | Avian sternal cartilage composition and method of administering | |
WO2008066308A1 (en) | Food composition for increasing the satiety and satiation | |
CN113924089A (zh) | 使用一种或多种自噬诱发氨基酸来增强一种或多种合成代谢氨基酸的肌肉骨骼效应的组合物和方法 | |
JP2007254440A (ja) | 脂質代謝調節剤及び脂質代謝調節食品 | |
JP2805194B2 (ja) | 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤 | |
JP6829186B2 (ja) | 海産物ペプチドおよび魚類ヌクレオチド、その組成物および血糖を低下させるためのその使用 | |
JP4808218B2 (ja) | 抗糖尿病作用を有する蛋白加水分解物 | |
JP2002020312A (ja) | 体脂肪減少促進用食品組成物及び体脂肪減少促進剤 | |
JP7516717B2 (ja) | フッ化物及びトリメチルアミン含量の低い海洋タンパク質加水分解物 | |
WO2015009225A1 (en) | Food composition product | |
JP5156330B2 (ja) | 脂肪組織重量減少剤 | |
WO2017001515A1 (en) | Marine peptides and muscle health | |
JPWO2006008890A1 (ja) | 筋肉増強組成物 | |
JPH09110686A (ja) | マクロファージ一酸化窒素産生亢進剤 | |
JPH07215851A (ja) | 抗アレルギー剤及びその製造法 | |
JPH10139681A (ja) | 水性乳化栄養組成物及びその用途 | |
JP2001026753A (ja) | 高血圧症予防又は治療用組成物 | |
JP2001233783A (ja) | 術前栄養剤 | |
JP4695629B2 (ja) | 難消化剤 | |
JP7436976B2 (ja) | 変性脱脂大豆を有効成分とする胃排出速度抑制剤 | |
JP5317456B2 (ja) | 内因性オピオイドペプチドの血中分泌促進用組成物 | |
JP2010006764A (ja) | タンパク同化促進剤 | |
JPH08157385A (ja) | 便通改善剤、腸粘膜増殖増強剤および経腸栄養剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180702 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190508 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190805 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200806 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201104 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6829186 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |